Title : Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).

Pub. Date : 2020 Feb

PMID : 32043796






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 IMPLICATIONS FOR PRACTICE: For RAS/RAF wild-type metastatic colorectal cancer, patients may receive 5-fluorouracil-based chemotherapy plus either bevacizumab or an anti-epidermal growth factor receptor (EGFR). Fluorouracil epidermal growth factor receptor Homo sapiens